13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case

Background. Vaccination coverage in patients with rheumatic diseases remains extremely low. Moreover, infections are the leading cause of death in such patients. Respiratory infections mortality is 2–5 times higher in adults with rheumatoid arthritis than in overall population. The most frequent inf...

Full description

Bibliographic Details
Main Authors: Ekaterina I. Alekseeva, Dar’ya D. Van’kova, Tatyana M. Dvoryakovskaya, Kseniya B. Isaeva, Rina V. Denisova, Anna V. Mamutova, Aleksandra M. Chomahidze, Nikolay A. Mayanskiy, Natalya E. Tkachenko, Maria V. Kurdup, Tatyana V. Radygina, Irina V. Zubkova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2019-09-01
Series:Voprosy Sovremennoj Pediatrii
Subjects:
children
pneumococcal disease
vaccination
13-valent pneumococcal conjugate vaccine
haemophilus influenzae-tetanus toxoid conjugate vaccine
tocilizumab
systemic juvenile idiopathic arthritis
Online Access:https://vsp.spr-journal.ru/jour/article/view/2137

Internet

https://vsp.spr-journal.ru/jour/article/view/2137

Similar Items